Delcath Systems Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
DCTH Nasdaq 3841 http://delcath.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Delcath Systems Inc

Delcath Systems Stock Jumps After Data Update From Eye Cancer Trials At ASCO Meeting - Jun 7th, 2022 11:06 am
Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting - Jun 6th, 2022 8:15 pm
Delcath Systems Reports First Quarter 2022 Results and Provides Business Update - May 10th, 2022 11:30 am
Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting - May 9th, 2022 12:30 pm
Is Delcath Systems (NASDAQ:DCTH) Using Too Much Debt? - May 2nd, 2022 7:02 pm
Delcath Systems to Host First Quarter 2022 Results - Apr 28th, 2022 1:00 pm
Delcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference - Apr 8th, 2022 1:00 pm
Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference - Mar 29th, 2022 1:00 pm
Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update - Mar 25th, 2022 11:30 am
Delcath Systems to Host Fourth Quarter and Full Year 2021 Results - Mar 15th, 2022 8:30 pm
Delcath Systems to Present at the 34th Annual Roth Conference - Mar 10th, 2022 2:00 pm
Delcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT® in Europe - Mar 2nd, 2022 9:01 pm
Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT® - Feb 22nd, 2022 2:00 pm
Delcath Systems to Present at Upcoming Virtual Investor Conferences - Feb 10th, 2022 9:30 pm
Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported - Feb 7th, 2022 9:01 pm
Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver - Feb 4th, 2022 2:00 pm
Results of Single Center Study on Delcath’s CHEMOSAT® Hepatic Delivery System Published in Melanoma Research - Feb 3rd, 2022 9:30 pm
David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary - Jan 25th, 2022 9:01 pm
Delcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022 - Jan 7th, 2022 2:00 pm
Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis - Dec 2nd, 2021 1:00 pm